These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 3928906)
21. Intravesical thiotepa in the treatment of transitional cell bladder carcinoma. Mitchell RJ Br J Urol; 1971 Apr; 43(2):185-8. PubMed ID: 4996214 [No Abstract] [Full Text] [Related]
22. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547 [TBL] [Abstract][Full Text] [Related]
23. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Farrow GM; Utz DC; Rife CC; Greene LF Cancer Res; 1977 Aug; 37(8 Pt 2):2794-8. PubMed ID: 406039 [TBL] [Abstract][Full Text] [Related]
24. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer. Seraphim LA; Perrapato SD; Slocum HK; Rustum YM; Huben RP J Urol; 1991 Mar; 145(3):613-7. PubMed ID: 1900087 [TBL] [Abstract][Full Text] [Related]
28. A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers. Flanigan RC; Ellison MF; Butler KM; Gomella LG; McRoberts JW J Urol; 1986 Jul; 136(1):35-7. PubMed ID: 3086575 [TBL] [Abstract][Full Text] [Related]
29. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813 [TBL] [Abstract][Full Text] [Related]
30. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016 [TBL] [Abstract][Full Text] [Related]
31. [Urinary cytology in cases of bladder cancer: a critical evaluation]. Rathert P Urologe A; 2003 Jul; 42(7):908-11. PubMed ID: 12898033 [TBL] [Abstract][Full Text] [Related]
34. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. Zincke H; Benson RC; Hilton JF; Taylor WF J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685 [TBL] [Abstract][Full Text] [Related]
35. [Reliability of urinary cytology for follow-up of bladder cancer]. Ginesin Y; Malberger E; Semberg S; Levin DR Harefuah; 1987 Sep; 113(5-6):101-3. PubMed ID: 3692366 [No Abstract] [Full Text] [Related]
36. Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma. Garnick MB; Schade D; Israel M; Maxwell B; Richie JP J Urol; 1984 Jan; 131(1):43-6. PubMed ID: 6690745 [TBL] [Abstract][Full Text] [Related]
37. [Clinical application of flow cytometry in urology. 3. Correlation between urinary cytology and flow cytometry]. Tachibana M; Nakamura S; Shibayama T; Jitsukawa S; Deguchi N; Baba S; Nakazono M; Hata M; Tazaki H Nihon Hinyokika Gakkai Zasshi; 1986 Nov; 77(11):1864-7. PubMed ID: 3573470 [No Abstract] [Full Text] [Related]